{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T10:46:31Z","timestamp":1783766791526,"version":"3.55.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T00:00:00Z","timestamp":1765411200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T00:00:00Z","timestamp":1768348800000},"content-version":"vor","delay-in-days":34,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100020595","name":"National Science and Technology Council","doi-asserted-by":"publisher","award":["NSTC 112-2314-B-038-083"],"award-info":[{"award-number":["NSTC 112-2314-B-038-083"]}],"id":[{"id":"10.13039\/100020595","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020953","name":"Taiwan Centers for Disease Control","doi-asserted-by":"publisher","award":["MOHW114-CDC-C114-000115"],"award-info":[{"award-number":["MOHW114-CDC-C114-000115"]}],"id":[{"id":"10.13039\/100020953","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>COVID-19 patients frequently present with various comorbidities. Two developed antiviral medications, nirmatrelvir\/ritonavir and molnupiravir, have been utilized in COVID-19 patients; but comparisons of the effectiveness between nirmatrelvir\/ritonavir and molnupiravir in COVID-19 patients with different comorbidities remain unknown. This study aims to compare the effectiveness, including invasive ventilation and mortality, of nirmatrelvir\/ritonavir and molnupiravir in the overall population and populations with various comorbidities in Taiwanese patients during the omicron BA.2 wave.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We retrospectively collected electronic medical records from the Taipei Medical University Clinical Research Database between January and December 2022 and conducted an analysis of adult patients diagnosed with SARS-CoV-2 infection. For data management, we performed propensity score matching to minimize the imbalance between two groups; the standardized mean difference\u2009&gt;\u20090.1 or a p value\u2009&lt;\u20090.05 considered statistically significant. Variables, which remained imbalanced after matching, were adjusted by cox regression model. To identify the risk associated with these variables, a Cox proportional hazards model were performed. Kaplan-Meier method was applied to estimate invasive ventilation and mortality, comparing survival curves between nirmatrelvir\/ritonavir users and molnupiravir users.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Our cohort was recruited from a database, including patients who receive nirmatrelvir\/ritonavir or molnupiravir treatment. Out of a total of 35,617 patients, 968 patients received nirmatrelvir\/ritonavir and 1198 patients received molnupiravir after matching. Patients with chronic liver disease or mental disease on nirmatrelvir\/ritonavir had lower risks of intubation than those on molnupiravir. Overall, nirmatrelvir\/ritonavir reduced mortality risk by 65% (adjusted hazard ratio (aHR): 0.35, 95% confidence interval (CI): 0.14\u20130.88,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.026). For patients with diabetes mellitus (aHR: 0.29, 95% CI: 0.11\u20130.78,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.014), with chronic kidney disease (aHR: 0.26, 95% CI: 0.10\u20130.68,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.007), or aged over 65 years (aHR: 0.30, 95% CI: 0.13\u20130.70,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.005), nirmatrelvir\/ritonavir demonstrated superior efficacy in reducing mortality risk compared to molnupiravir.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Data revealed that both nirmatrelvir\/ritonavir and molnupiravir demonstrated clinical benefits in treating COVID-19 patients in a real-world setting. Moreover, nirmatrelvir\/ritonavir was associated with a lower risk of mortality in COVID-19 patients with specific circumstances.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical trial<\/jats:title>\n                    <jats:p>Clinical trial number is not applicable.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12879-025-12316-0","type":"journal-article","created":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T16:27:14Z","timestamp":1765470434000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Effectiveness comparison of nirmatrelvir\/ritonavir versus molnupiravir in COVID-19 patients with comorbidities in Taiwan: a multi-centre electronic health record study"],"prefix":"10.1186","volume":"26","author":[{"given":"Wen-Kuang","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shwu-Jiuan","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Hui","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fu-Der","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phung-Anh","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phan Thanh","family":"Phuc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Whitney","family":"Burton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nguyen Thi Kim","family":"Hien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chia-Chieh","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos Shu-Kei","family":"Lam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"To-Chi","family":"Ha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine Y.","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chih-Wei","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsuan-Chia","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiue-Ming","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chieh","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Hsuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason C.","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,11]]},"reference":[{"key":"12316_CR1","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1038\/s41419-020-02995-9","volume":"11","author":"S Platto","year":"2020","unstructured":"Platto S, Xue TT, Carafoli E. COVID19: an announced pandemic. Cell Death Dis. 2020;11:799.","journal-title":"Cell Death Dis"},{"key":"12316_CR2","doi-asserted-by":"publisher","first-page":"104327","DOI":"10.1016\/j.meegid.2020.104327","volume":"83","author":"TM Abd El-Aziz","year":"2020","unstructured":"Abd El-Aziz TM, Stockand JD. Recent progress and challenges in drug development against COVID-19 coronavirus (SARS-COV-2) \u2013 an update on the status. Infect Genet Evol. 2020;83:104327.","journal-title":"Infect Genet Evol"},{"key":"12316_CR3","unstructured":"WHO. Available online: WHO coronavirus (COVID-19) dashboard | WHO coronavirus (COVID-19) dashboard with vaccination data. https:\/\/data.who.int\/dashboards\/covid19\/cases?n=c. Assessed 20 April 2025."},{"key":"12316_CR4","doi-asserted-by":"publisher","first-page":"582932","DOI":"10.3389\/fpubh.2020.582932","volume":"8","author":"OP Mehta","year":"2021","unstructured":"Mehta OP, Bhandari P, Raut A, Oussama Kacimi SE, Huy NT. Coronavirus disease (COVID-19): comprehensive review of clinical presentation. Front Public Health. 2021;8:582932.","journal-title":"Front Public Health"},{"key":"12316_CR5","doi-asserted-by":"publisher","first-page":"2348","DOI":"10.1056\/NEJMoa2105290","volume":"385","author":"AR Falsey","year":"2021","unstructured":"Falsey AR, Sobieszczyk ME, Hirsch I, Sproule S, Math M, Robb ML, et al. Phase 3 safety and efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 vaccine. N Engl J Med. 2021;385:2348\u201360.","journal-title":"N Engl J Med"},{"key":"12316_CR6","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","volume":"383","author":"FP Polack","year":"2020","unstructured":"Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383:2603\u201315.","journal-title":"N Engl J Med"},{"key":"12316_CR7","doi-asserted-by":"publisher","first-page":"1774","DOI":"10.1056\/NEJMoa2113017","volume":"385","author":"EI Sahly","year":"2021","unstructured":"EI Sahly HM, Baden LR, Essink B, Doblecki-Lewis S, Martin JM, Anderson EJ, et al. Efficacy of the mRNA-1273 SARS-CoV-2 vaccine at completion of blinded phase. N Engl J Med. 2021;385:1774\u201385.","journal-title":"N Engl J Med"},{"key":"12316_CR8","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1111\/bcp.15552","volume":"89","author":"S Kumar","year":"2023","unstructured":"Kumar S, Basu M, Ghosh P, Ansari A, Ghosh MK. COVID-19: clinical status of vaccine development to date. Br J Clin Pharmacol. 2023;89:114\u201349.","journal-title":"Br J Clin Pharmacol"},{"key":"12316_CR9","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1056\/NEJMoa2118542","volume":"386","author":"J Hammond","year":"2022","unstructured":"Hammond J, Leister-Tebbe H, Gardner A, Abreu P, Bao WH, Wisemandle W, et al. Oral nirmatrelvir for high-risk, nonhospitalized adults with COVID-19. N Engl J Med. 2022;386:1397\u2013408.","journal-title":"N Engl J Med"},{"key":"12316_CR10","doi-asserted-by":"publisher","first-page":"EVIDoa2100043","DOI":"10.1056\/EVIDoa2100043","volume":"1","author":"Y Caraco","year":"2022","unstructured":"Caraco Y, Crofoot GE, Moncada PA, Galustyan AN, Musungaie DB, Payne B, et al. Phase 2\/3 trial of molnupiravir for treatment of Covid-19 in nonhospitalized adults. NEJM Evid. 2022;1:EVIDoa2100043.","journal-title":"NEJM Evid"},{"key":"12316_CR11","doi-asserted-by":"publisher","first-page":"e00909","DOI":"10.1002\/prp2.909","volume":"10","author":"F Pourkarim","year":"2022","unstructured":"Pourkarim F, Pourtaghi-Anvarian S, Rezaee H, Molnupiravir. A new candidate for COVID-19 treatment. Pharmacol Res Perspect. 2022;10:e00909.","journal-title":"Pharmacol Res Perspect"},{"key":"12316_CR12","doi-asserted-by":"publisher","first-page":"e100890","DOI":"10.1136\/bmjhci-2023-100890","volume":"31","author":"PA Nguyen","year":"2024","unstructured":"Nguyen PA, Hsu MH, Chang TH, Yang HC, Huang CW, Liao CT, et al. Taipei medical university clinical research database (TMUCRD) \u2013 A collaborative hospital HER database aligned with international common data standards. BMJ Health Care Inf. 2024;31:e100890.","journal-title":"BMJ Health Care Inf"},{"key":"12316_CR13","unstructured":"Murphy SJ, Samson LW, Sommers BD. COVID-19 antivirals utilization: geographic and demographic patterns of treatment in 2022. https:\/\/aspe.hhs.gov\/sites\/default\/files\/documents\/a19600d0dccfee0e9c595730d73fd66d\/covid-antivirals-report.pdf. Assessed 20 April 2025."},{"key":"12316_CR14","unstructured":"Taiwan centers of disease control. Available online: CECC announces evaluation process for receiving oral antiviral drugs for individuals aged 65 and older who are not under home isolation\/quarantine\/self-initiated epidemic prevention and test positive with rapid tests starting May 18 - Taiwan Centers for Disease Control. https:\/\/www.cdc.gov.tw\/En\/Bulletin\/Detail\/_TfxyFQh0tO0-GiOeMyoxA?typeid=158. Assessed 20 April 2025."},{"key":"12316_CR15","unstructured":"Taiwan Centers of Disease Control. Covid-19 Vaccine Statistics, website: http:\/\/at.cdc.gov.tw\/2dL406. Assessed 20 April 2025."},{"key":"12316_CR16","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1080\/07853890.2022.2034936","volume":"54","author":"W Wen","year":"2022","unstructured":"Wen W, Chen C, Tang J, Wang C, Zhou M, Cheng Y, et al. Efficacy and safety of three new oral antiviral treatment (molnupiravir, fluvoxamine, Paxlovid) for COVID-19: a meta-analysis. Ann Med. 2022;54:516\u201323.","journal-title":"Ann Med"},{"key":"12316_CR17","doi-asserted-by":"publisher","first-page":"e671","DOI":"10.1002\/hsr2.671","volume":"5","author":"T Islam","year":"2022","unstructured":"Islam T, Hasan M, Rahman MS, Islam MR. Comparative evaluation of authorized drugs for treating COVID-19 patients. Health Sci Rep. 2022;5:e671.","journal-title":"Health Sci Rep"},{"key":"12316_CR18","doi-asserted-by":"publisher","first-page":"e28441","DOI":"10.1002\/jmv.28441","volume":"95","author":"B Amani","year":"2023","unstructured":"Amani B, Amani B. Efficacy and safety f nirmatrelvir\/ritonavir (Paxlovid) for COVID-19: A rapid review and meta-analysis. J Med Virol. 2023;95:e28441.","journal-title":"J Med Virol"},{"key":"12316_CR19","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1016\/S1473-3099(23)00118-4","volume":"23","author":"JA Lewnard","year":"2023","unstructured":"Lewnard JA, McLaughlin JM, Malden D, Hong V, Puzniak L, Ackerson BK, et al. Effectiveness of nirmatrelvir-ritonavir in preventing hospital admissions and deaths in people with COVID-19: a cohort study in a large US healthcare system. Lancet Infect Dis. 2023;23:806\u201315.","journal-title":"Lancet Infect Dis"},{"key":"12316_CR20","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1016\/S0140-6736(22)01586-0","volume":"400","author":"CKH Wong","year":"2022","unstructured":"Wong CKH, Au ICH, Lau KTK, Lau EHY, Cowling BJ, Leung GM. Real-world effectiveness of molnupiravir and nirmatrelvir plus Ritonavir against mortality, hospitalization, and in-hospital outcomes among community-dwelling, ambulatory patients with confirmed SARS-CoV-2 infection during the Omicron wave in Hong kong: an observational study. Lancet. 2022;400:1213\u201322.","journal-title":"Lancet"},{"key":"12316_CR21","doi-asserted-by":"publisher","first-page":"e28889","DOI":"10.1002\/jmv.28889","volume":"95","author":"B Amani","year":"2023","unstructured":"Amani B, Akbarzadeh A, Amani B, Shabestan R, Khorramnia S, Navidi Z, et al. Comparative efficacy and safety of nirmatrelvir\/ritonavir than molnupiravir for COVID-19: A systematic review and meta-analysis. J Med Virol. 2023;95:e28889.","journal-title":"J Med Virol"},{"key":"12316_CR22","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/S1473-3099(23)00493-0","volume":"24","author":"WHK Schilling","year":"2024","unstructured":"Schilling WHK, Jittamala P, Watson JA, Boyd S, Luvira V, Siripoon T, et al. Antiviral efficacy of molnupiravir versus ritonavir-boosted nirmatrelvir in patients with early symptomatic COVID-19 (PLATCOV): an open-label, phase 2, randomised, controlled, adaptive trial. Lancet Infect Dis. 2024;24:36\u201345.","journal-title":"Lancet Infect Dis"},{"key":"12316_CR23","doi-asserted-by":"publisher","first-page":"105659","DOI":"10.1016\/j.antiviral.2023.105659","volume":"216","author":"H Cai","year":"2023","unstructured":"Cai H, Yan J, Liu S, Li P, Ding L, Zhan Y, et al. Paxlovid for hospitalized COVID-19 patients with chronic kidney disease. Antiviral Res. 2023;216:105659.","journal-title":"Antiviral Res"},{"key":"12316_CR24","doi-asserted-by":"publisher","first-page":"e342","DOI":"10.1093\/cid\/ciac443","volume":"76","author":"R Najjar-Debbiny","year":"2023","unstructured":"Najjar-Debbiny R, Gronich N, Weber G, Khoury J, Amar M, Stein N, et al. Effectiveness of paxlovid in reducing severe coronavirus disease 2019 and mortality in high-risk patients. Clin Infect Dis. 2023;76:e342\u20139.","journal-title":"Clin Infect Dis"},{"key":"12316_CR25","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1080\/14787210.2024.2339398","volume":"22","author":"CK Hsu","year":"2024","unstructured":"Hsu CK, Hsu WH, Shiau BW, Tsai YW, Wu JY, Liu TH, et al. The effectiveness of novel oral antiviral treatment for non-hospitalized high-risk patients with COVID-19 during predominance of omicron XBB subvariants. Expert Rev Anti Infect Ther. 2024;22:785\u201392.","journal-title":"Expert Rev Anti Infect Ther"},{"key":"12316_CR26","doi-asserted-by":"publisher","first-page":"e2314393","DOI":"10.1001\/jamanetworkopen.2023.14393","volume":"6","author":"DTW Lui","year":"2023","unstructured":"Lui DTW, Chung MSH, Lau EHY, Lau KTK, Au ICH, Lee CH, et al. Analysis of all-cause hospitalization and death among nonhospitalized patients with type 2 diabetes and SARS-CoV-2 infection treated with molnupiravir or nirmatrelvir-ritonavir during the Omicron wave in Hong Kong. JAMA Netw Open. 2023;6:e2314393.","journal-title":"JAMA Netw Open"},{"key":"12316_CR27","doi-asserted-by":"publisher","first-page":"e2336678","DOI":"10.1001\/jamanetworkopen.2023.36678","volume":"6","author":"CR Dormuth","year":"2023","unstructured":"Dormuth CR, Kim JD, Fisher A, Piszczek J, Kuo IF. Nirmatrelvir-Ritonavir and COVID-19 mortality and hospitalization among patients with vulnerability to COVID-19 complications. JAMA Netw Open. 2023;6:e2336678.","journal-title":"JAMA Netw Open"},{"key":"12316_CR28","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s42358-024-00388-6","volume":"64","author":"F Javed","year":"2024","unstructured":"Javed F, Mangino AA, Piranavan P. Nirmatrelvir plus Ritonavir in patients with underlying rheumatological diseases, in preventing COVID-19 related hospitalization and death. Adv Rheumatol. 2024;64:50.","journal-title":"Adv Rheumatol"},{"key":"12316_CR29","doi-asserted-by":"publisher","first-page":"101939","DOI":"10.1016\/j.eclinm.2023.101939","volume":"58","author":"J Salmanton-Garcia","year":"2023","unstructured":"Salmanton-Garcia J, Marchesi F, Gomes da Silva M, Farina F, Davila-Valls J, Bilgin YM, et al. Nirmatrelvir-ritonavir in COVID-19 patients with haematological malignancies: a report from EPICOVIDEHA registry. EClinicalMedicine. 2023;58:101939.","journal-title":"EClinicalMedicine"},{"key":"12316_CR30","doi-asserted-by":"publisher","first-page":"1321155","DOI":"10.3389\/fphar.2024.1321155","volume":"15","author":"CC Yang","year":"2024","unstructured":"Yang CC, Tsai YW, Wang SH, Wu JY, Liu TH, Hsu WH, et al. The effectiveness of oral anti-SARS-CoV-2 agents in non-hospitalized COVID-19 patients with nonalcoholic fatty liver disease: a retrospective study. Front Pharmacol. 2024;15:1321155.","journal-title":"Front Pharmacol"},{"key":"12316_CR31","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1007\/s15010-022-01959-9","volume":"51","author":"MG Johnson","year":"2023","unstructured":"Johnson MG, Strizki JM, Brown ML, Wan H, Shamsuddin HH, Ramgopal M, et al. Molnupiravir for the treatment of COVID-19 in immunocompromised participants: efficacy, safety, and virology results from the phase 3 randomized, placebo-controlled MOVe-OUT trial. Infection. 2023;51:1273\u201384.","journal-title":"Infection"},{"key":"12316_CR32","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1002\/ijc.34442","volume":"153","author":"L Bolkun","year":"2023","unstructured":"Bolkun L, Pula B, KolKowska-Lesniak A, Morawska M, Cichocka E, Charlinski G, et al. Molnupiravir is effective in patients with haematological malignancies. Int J Cancer. 2023;153:1251\u20136.","journal-title":"Int J Cancer"},{"key":"12316_CR33","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1016\/j.ekir.2024.02.009","volume":"9","author":"FWT Cheng","year":"2024","unstructured":"Cheng FWT, Yan VKC, Wan EYF, Chui CSL, Lai FTT, Wong CKH, et al. Effectiveness of molnupiravir and nirmatrelvir-ritonavir in CKD patients with COVID-19. Kidney Int Rep. 2024;9:1244\u201353.","journal-title":"Kidney Int Rep"},{"key":"12316_CR34","doi-asserted-by":"publisher","first-page":"102620","DOI":"10.1016\/j.eclinm.2024.102620","volume":"72","author":"WM Chu","year":"2024","unstructured":"Chu WM, Wan Erick YF, Wong Zoey CT, Tam AR, Wong Ian CK, Chan Esther WY, et al. Comparison of safety and efficacy between nirmatrelvir-ritonavir and molnupiravir in the treatment of COVID-19 infections in patients with advanced kidney disease: a retrospective observational study. EClinicalMedicine. 2024;72:102620.","journal-title":"EClinicalMedicine"},{"key":"12316_CR35","doi-asserted-by":"publisher","first-page":"4653","DOI":"10.1111\/dom.15830","volume":"26","author":"YF Wan Erick","year":"2024","unstructured":"Wan Erick YF, Wong Zoey CT, Yan Vincent KC, Chui Celine SL, Lai Francisco TT, Li X, et al. Comparing the effectiveness of molnupiravir and nirmatrelvir-ritonavir in non-hospitalized and hospitalized COVID-19 patients with type 2 diabetes: A target trial emulation study. Diabetes Obes Metab. 2024;26:4653\u201364.","journal-title":"Diabetes Obes Metab"},{"key":"12316_CR36","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.3390\/cancers16051055","volume":"16","author":"AJ Haddad","year":"2024","unstructured":"Haddad AJ, Hachem RY, Moussa M, Jiang Y, Dagher HR, Chaftari P, et al. Comparing molnupiravir to Nirmatrelvir\/Ritonavir (Paxlovid) in the treatment of Mild-to-Moderate COVID-19 in immunocompromised cancer patients. Cancers (Basel). 2024;16:1055.","journal-title":"Cancers (Basel)"},{"key":"12316_CR37","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/j.jmii.2023.04.001","volume":"56","author":"CC Lai","year":"2023","unstructured":"Lai CC, Lee PI, Hsueh PR. How Taiwan has responded to COVID-19 and how COVID-19 has affected Taiwan, 2020\u20132022. J Microbiol Immunol Infect. 2023;56:433\u201341.","journal-title":"J Microbiol Immunol Infect"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-025-12316-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-025-12316-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-025-12316-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T11:49:21Z","timestamp":1768391361000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12879-025-12316-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,11]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["12316"],"URL":"https:\/\/doi.org\/10.1186\/s12879-025-12316-0","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,11]]},"assertion":[{"value":"12 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This research using anonymized existing health data without any direct intervention on the participants, was reviewed and approved by the Joint Institutional Review Board of Taipei Medical University (TMUJIRB no.: N202302013). A requirement for consent from study participants was waived by the TMUJIRB as the study used anonymized data from Taipei Medical University Clinical Research Database with no physical patient contact. The study was completed in accordance with the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"70"}}